Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Zhi Yao Chan"'
Autor:
Jia Li Low, Yiqing Huang, Kenneth Sooi, Zhi Yao Chan, Wei Peng Yong, Soo Chin Lee, Boon Cher Goh
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
The rising cost of oncological drugs poses a global challenge to patients, insurers, and policy makers, with the leading drugs worldwide by revenue from immune checkpoint inhibitors (ICIs). Despite its cost, ICI is marked as a paradigm shift, offerin
Externí odkaz:
https://doaj.org/article/0dd5ed50793047ff8ca7f044e506b976
Autor:
Zhi Yao Chan, Chen Fang Lim, Jo Lene Leow, Feng Yong Chium, Su Wen Lim, Charlotte Hui Min Tong, Jessie Jie Xi Zhou, Moses Min Yuan Tsi, Ryan Ying Cong Tan, Lita Sui Tjien Chew
Publikováno v:
Proceedings of Singapore Healthcare, Vol 31 (2022)
Background: Telemedicine has demonstrated benefits for cancer patients including the potential to improve care coordination and patient outcomes. Since June 2020, teleconsultations have been implemented in the National Cancer Centre Singapore. Object
Externí odkaz:
https://doaj.org/article/fb57fa043b7d4baab4c94797e1efa4bc
Autor:
Natalie Yl Ngoi, Yvonne Le Ang, Yiqing Huang, Wan Qin Chong, Ross A. Soo, Gloria Chan, Joan Re Choo, Zhi Yao Chan, Alvin Wong, Vaishnavi Muthu, Jia Li Low, Yong Xiang Gwee
Publikováno v:
Lung Cancer. 146:145-153
Background The importance of immune-checkpoint inhibitors (ICI) can no longer be understated since its move to front-line treatment in non-small cell lung cancer (NSCLC) in recent years. However, the safety and efficacy of ICI in special populations
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::66dd9879593e5876491058484878b753
https://doi.org/10.1016/j.lungcan.2020.05.020
https://doi.org/10.1016/j.lungcan.2020.05.020
Autor:
Constance Teo, Mary Chong, Siew Woon Lim, Yen-Lin Chee, Ednajoy Ngo, Meng Tuck Lee, Yee Mei Lee, Cheng Ean Chee, Yuet Peng Wong, Judith Lee, Mariana Ibrahim, Wei-Ying Jen, Melinda Khoo, Rui Xian Tay, Zhi Yao Chan, Noel Ng, Belinda Tan
Publikováno v:
Blood. 136:18-20
Introduction Chemotherapy is a dynamic, complex process involving cross-functional healthcare teams and comprises dosing, scheduling, safety checks, compounding and administration. Coupled with team silos, legacy systems, escalating workload and cost
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c5e0e6d92641076ab9abc6cc6abff5e1
https://doi.org/10.1182/blood-2020-138603
https://doi.org/10.1182/blood-2020-138603
Autor:
Jia Li Low, Yiqing Huang, Wei Peng Yong, Raghav Sundar, K. Spencer, Kenneth Sooi, Yvonne Ang, Boon Cher Goh, Ross A. Soo, Anand D. Jeyasekharan, Zhi Yao Chan
Publikováno v:
International journal of cancer. 149(1)
A dose of 200 mg 3-weekly of pembrolizumab was approved by the Food and Drug Administration (FDA) as treatment for advanced non-small cell lung cancer (NSCLC) without oncogenic drivers. This is despite evidence showing no difference in efficacy with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1a22164b0c7816ae597902e212769583
https://pubmed.ncbi.nlm.nih.gov/33634869
https://pubmed.ncbi.nlm.nih.gov/33634869
Autor:
Zhi Yao Chan, Raghav Sundar, Matilda Lee, Robert John Walsh, Hon Lyn Tan, Yvonne Ang, Jia Li Low, Yiqing Huang, Kenneth Sooi, Joan Choo, Ross A. Soo, Wei Peng Yong, Yugarajah Asokumaran, Natalie Ngoi, Gloria Chan, Rachel Su Jen Wong, Vaishnavi Muthu, Wan Qin Chong
Publikováno v:
Journal of Clinical Oncology. 38:e19385-e19385
e19385 Background: Pembrolizumab has dramatically improved the survival of patients with non-small cell lung cancer (NSCLC) and is considered the standard of care for first line treatment of NSCLC who do not harbour oncogenic drivers. The fixed dose
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b25488f7e2ebca3997e20618fedb7834
https://doi.org/10.1200/jco.2020.38.15_suppl.e19385
https://doi.org/10.1200/jco.2020.38.15_suppl.e19385